有没有人知道Regeneron's monoclonal antibody treatment va1682021-08-18 00:32:28

Regeneron Pharmaceuticals (REGN) said Friday that the US Food and Drug Administration expanded the emergency use authorization for the investigational COVID-19 antibody cocktail REGEN-COV, or casirivimab and imdevimab to include post-exposure prophylaxis in people at high risk for progression to severe COVID-19

REGEN-COV can also be administered every month in patients requiring repeat dosing for ongoing exposure, but is not a substitute for vaccination against COVID-19. The new indication in people 12 years and older is in addition to the previously authorization to treat non-hospitalized patients.

Under the emergency use authorization for post-exposure prophylaxis, REGEN-COV can be administered by subcutaneous injection or intravenous infusion.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19